McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-6.
Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-603.
Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982; 47: 412-26.
Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94: 771-8.
Fuster V, Gotto AM Jr. Risk reduction. Circulation 2000; 102(20 Suppl 4):IV94-102.
Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109(21 Suppl 1): II2-10.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
Ministry of Health Welfare. Korea health statistics 2014: Korea national health and nutrition examination survey(KNHANES IV-6). Osong: Korea Centers for Disease Control and Prevention: 2015.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-34.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006; 21: 695-700.
Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, SuttonTyrrell K, et al. Inflammatory markers and onset of cardiovascular events:results from the Health ABC study. Circulation 2003; 108: 2317-22.
Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. CReactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-8.
Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-4.
Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-43.
Omar MA, Seedat MA, Dyer RB, Motala AA, Knight LT, Becker PJ. South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care 1994; 17: 70-3.
de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Causespecific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.
Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.
Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.
Bjørnholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 1999; 22: 45-9.
Yun YS, Park SW, Song YD, Park HK, Kim OY, Ahn CW, et al. Limitation of validity of homeostasis model assessment as a index of insulin resistance. J Korean Diabetes Assoc 2000; 24: 541-51.
Kang ES, Yun YS, Park SW, Kim HJ, Ahn CW, Song YD, et al. Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 2005; 54: 206-11.
Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15:74-80.
Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998; 21: 649-54.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-200.